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IgA autoantibodies from the sera of some patients with
linear IgA bullous dermatosis (LABD) recognize a 97
kDa antigen (LABD97) located in the lamina lucida of
the basement membrane zone. As LABD autoantibodies
do not react with the 180 and 230 kDa proteins recognized
by bullous pemphigoid autoantibodies, LABD97 has been
thought to represent a separate lamina lucida protein. In
this study, we purified LABD97 from the extract of human
epidermis using a monoclonal antibody immunoaffinity
column and analyzed the amino acid sequence of the
N terminus of purified LABD97. This revealed a 16 amino
acid sequence that was identical to a previously reported
sequence of the 180 kDa antigen in bullous pemphigoid
(BPAg2). The N terminus was located 41 amino acids
downstream from the carboxyl end of the transmembrane
domain of BPAg2 and 11 amino acids downstream from
the MCW-1 domain, the predominant bullous pemphig-
Linear IgA bullous dermatosis (LABD) is a rare acquiredsubepidermal blistering disease of the skin that has beendefined on the basis of its unique immunopathologic findingof linear IgA along the cutaneous basement membrane(Chorzelski and Jablonska, 1979). Immunoelectron micro-
scopy in LABD reveals three patterns of IgA deposition: sublamina
densa deposition densa, lamina lucida deposition, and deposition in
both locations (Stingl et al, 1976; Yaoita and Katz, 1977; Bhogal et al,
1987; Prost et al, 1989). We have previously described a 97 kDa
antigen (LABD97) extracted from human epidermis that binds IgA
basement membrane zone (BMZ) antibodies from sera of patients with
the lamina lucida type of LABD (Zone et al, 1990).
Bullous pemphigoid (BP) patients demonstrate deposition of IgG
antibody along the basement membrane on direct immunofluorescence.
Two BMZ antigens have been described that react with circulating
IgG antibodies from patients with BP: BPAg1 is a 230 kDa intracellular
protein located in the anchoring plaque of the hemidesmosome (Stanley
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oid epitope. Purified LABD97 was subsequently
enzymatically digested with endoproteinase Arg C and
separated by chromatography, which resulted in multiple
peptide fractions. Fourteen of these fractions were sub-
jected to amino acid sequencing. The amino acid
sequence of the peptide fractions, totaling 205 amino
acids, were identical to sequences contained within the
extracellular domain of BPAg2. Whereas the predominant
epitope identified with bullous pemphigoid sera is located
in the noncollagenous region of this protein, the epitope
recognized by LABD sera is either within or adjacent to
the collagenous portion. We conclude that LABD97
represents a portion of the extracellular domain of BPAg2
and that the IgA autoantibodies are directed against an
epitope within or adjacent to a collagenous domain. Key
words: basement membrane/blisters/skin. J Invest Dermatol
110:207–210, 1998
et al, 1988); BPAg2 is a 180 kDa transmembrane protein with a
noncollagenous intracellular and a predominantly collagenous extracel-
lular component (Diaz et al, 1990; Giudice et al, 1992). Epitope
mapping with fusion proteins containing segments of BPAg2 has
localized the reactive site to a 14 amino acid sequence of the NC16a
domain of the extracellular portion of BPAg2, as shown in Fig 1
(Giudice et al, 1993).
Our initial studies showed that LABD sera that reacted with LABD97
did not cross-react with BPAg2 (Zone et al, 1990) and these findings
have been confirmed by others (Dmochowski et al, 1993). Subsequent
collaboration with Marinkovich et al demonstrated that LABD97 shared
immunologic identity with a 120 kDa protein produced by cultured
keratinocytes (Marinkovich et al, 1996). With these data, we had
concluded that LABD97 was a unique protein distinct from BPAg2
and a fragment of a larger 120 kDa protein. In this study, however,
we present convincing evidence based on amino acid sequencing of
purified LABD97 that LABD97 is identical to a portion of the
extracellular portion of BPAg2.
MATERIALS AND METHODS
Preparation of human skin extract Extract enriched for LABD97 was
prepared as described (Zone et al, 1996). Briefly, human skin was separated
overnight in 1 M NaCl at 4°C. The epidermal and dermal washes were pooled
and passed over a DEAE-Sepharose column. After washing the column with
0.15 M NaCl, all remaining protein was eluted with 0.4 M NaCl. This fraction
was passed over a hydroxyapatite column that was washed with 80 mM
phosphate buffer and the remaining bound protein was removed with 160 mM
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Figure 1. Schematic representation of BPAg2. As described by Giudice
et al (1992), BPAg2 is a transmembrane protein with an carboxy-terminal
extracellular domain containing 1007 amino acids. This extracellular domain
contains 15 collagenous domains. The noncollagenous NC16a domain contains
the epitope recognized by BP autoantibodies. (GenBank Accession Number
I56325; used with permission from G. Giudice, personal communication.)
phosphate buffer. This last eluate, which contains the LABD97 antigen, was
concentrated by Centricon 30 centrifugation before being stored at –80°C.
Production of monoclonal antibodies LABD97, purified by elution from
a polyvinylidene difluoride (PVDF) membrane, was combined with Freund’s
complete adjuvant and injected intraperitoneally into BALB/C mice (Szewczyk
and Summers, 1992). Two weeks later the mice were boosted with a second
injection coupled with Freund’s incomplete adjuvant. The mice were sacrificed
2 wk after the second injection and the spleen removed. Spleen lymphocytes
were fused with 1 3 107 P3 3 63-AG8.653 myeloma cells and the hybridoma
cells were grown as described (Harlow and Lane, 1988). Culture supernatants
were screened by indirect immunofluorescence on ethylenediamine tetraacetic
acid-split human skin. Two positive hybridomas, MoAb 97–1 and MoAb 97–
2, were cloned by limiting dilution. Clones were injected intraperitoneally into
Freund’s incomplete adjuvant-primed BALB/C mice. Both monoclonals were
typed as IgG1 mouse antibodies by agar gel immunodiffusion. After delipidation,
mouse ascites containing the monoclonal antibodies was repeatedly passed over
a Sepharose Protein G column and the bound antibodies eluted with 0.1 M
acetic acid, pH 2.8.
Immunoaffinity purification of LABD97 Human skin extract enriched
for LABD97 was purified using an avidin-biotin immunoaffinity column. MoAb
97–1, purified from mouse ascites (see above), was labeled with biotin (Bayer
and Wilchek, 1980). Briefly, biotinamidocaproic acid 3-sulfo-N-hydroxysuccini-
mide ester was added to the antibody at a molar ratio of 3:1 in 0.1 M borate
buffer, pH 8.8. The biotin-antibody solution was passed over a G-10 desalting
column to remove unbound biotin. The biotinylated antibody (1 ml) was
serially applied to a 1 ml agarose streptavidin column. The column was washed
with 0.1 M acetic acid, pH 2.8, between each addition of the biotinylated
antibody. The resultant avidin-biotin column (200 µl) was washed with acetic
acid and phosphate-buffered saline before addition of the extract containing
LABD97. Six hundred microliters of extract were serially applied to the column
in 200 µl increments with a 203bed volume phosphate-buffered saline wash
between each addition. The bound LABD97 was eluted from the column with
0.1 M acetic acid, pH 2.8, and the eluate’s pH was adjusted to 7.0. The
purified LABD97 was analyzed with sodium dodecyl sulfate polyacrylamide gel
electrophoresis and western immunoblots.
N-amino terminal sequencing The LABD97 purified on the immunoaffin-
ity column was electrophoresed and transferred to the PVDF membrane. The
membrane was stained with Coomassie blue and the 97 kDa protein band was
identified and excised. This portion of the PVDF membrane containing only
the 97 kDa protein was submitted for N-amino terminus sequencing on an
Applied Biosystems 477 A pulse-liquid phase sequencer connected on-line to
a model 120 A PTH-amino acid analyzer (Charbonneau, 1993).
Proteolysis and partial peptide sequencing After the electrophoretic
transfer of purified LABD97 onto the PVDF membrane, the protein was
visualized by staining with Ponceau S. The portion of the membrane containing
the antigen was cut out, the stain removed by washing, and the membrane
diced into pieces not exceeding 2 mm2. The diced membrane was placed in a
microcentrifuge tube containing 1.5 µg of endoproteinase Arg C in a 50 µl
solution containing 1% RTX-100/10% acetonitrile/2 mM dithiothreitol/1 mM
CaCl2/100 mM Tris, pH 7.5, and incubated for 24 h at 37°C. Following
digestion, the peptides were sonicated for 5 min in a water bath, centrifuged
at 1700 r.p.m. for 5 min, transferred to a new tube, and stored at –20°C
(Fernandez et al, 1994).
The digest was injected into a Vydac 218 TP52 column (2.1 mm 3 250 mm)
Figure 2. Monoclonal antibody to LABD97 stains the epidermal side
of BMZ-split human skin. Normal human skin was split at the BMZ with
20 mM ethylenediamine tetraacetic acid and used as a substrate for indirect
immunofluorescence. Both MoAb 97–1 and MoAb 97–2 (not shown), purified
from mouse ascites and used at a 1:100 dilution, stain the epidermal side of
split skin in a pattern identical to that seen with LABD anti-sera. Scale bar, 50 µm.
Figure 3. The monoclonal antibodies MoAb 97–1 and MoAb 97–2 stain
a 97 kDa protein on immunoblot. Proteins extracted from human epidermal
wash enriched for LABD97 (40 µg per lane) were separated with 6.5%
sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to
nitrocellulose. Lanes were incubated with normal human serum (lane C1) and
LABD patient serum (lane C2) at a 1:10 dilution, MoAb 97–1 (ascites fluid,
lane 1), or MoAb 97–2 (ascites fluid, lane 2) diluted 1:100. Both monoclonal
antibodies bound a 97 kDa protein in a pattern identical to that seen with
LABD serum.
that had been equilibrated in 0.1% trifluoroacetic acid. Peptides were eluted at
125 µl per min with a linear gradient up to 72% over 90 min and stored at –
80°C. Selected peptides were sequenced as described above.
RESULTS
MoAb 97–1 and MoAb 97–2 are specific for LABD97
Cryosections of BMZ-split human skin were incubated with MoAb
97–1 and MoAb 97–2 and fluoroscein isothiocyanate-conjugated
goat anti-mouse antibody using standard indirect immunofluorescent
techniques (Zone et al, 1990). Both monoclonal antibodies labeled the
epidermal side of the basement membrane of human skin (Fig 2) in a
staining pattern identical to that seen with LABD patient serum. No
immunoreactivity was seen within the epidermis or on the dermal side
of the basement membrane. Human skin extract enriched for LABD97
incubated with MoAb 97–1 and MoAb 97–2 revealed specific reactivity
with a 97 kDa protein on immunoblot (Fig 3, lanes 1 and 2). Serum
from a patient with LABD labeled a 97 kDa protein appearing at the
same position as the protein bound by the monoclonal antibodies
(Fig 3, lane C2).
LABD97 is purified using an immunoaffinity column LABD97
was purified from human skin extract using an immunoaffinity column
coupled with MoAb 97–1. Western blot analysis of the eluate revealed
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Figure 4. LABD97 was purified using an immunoaffinity column. An
immunoaffinity column was prepared as described in Materials and Methods using
MoAb 97–1. The bound protein was eluted from the column, separated on a
6.5% sodium dodecyl sulfate gel (lane 1, µ1 µg protein; lane 2, µ10 µg protein)
and transferred to nitrocellulose. Immunoblot analysis of lane 1, using LABD
serum (1:10 dilution), revealed the purified 97 kDa protein. This protein was
also seen on Coomassie blue staining of lane 2, as well as mouse heavy chain
protein at 55 kDa. HMW, high molecular weight standards.
Figure 5. LABD97 has multiple regions of sequence identity with the
extracellular domain of BPAg2. The deduced amino acid sequence of the
carboxyl two thirds of BPAg2 is shown (Giudice et al, 1992). The transmembrane
domain is indicated by the dotted underline and the putative bullous
pemphigoid/herpes gestationis epitope is indicated in bold lettering. The N-
terminal amino acid sequence of LABD97 (double underline) is identical to an
extracellular portion of BPAg2, downstream from the transmembrane domain.
Amino acid sequencing of 14 internal peptides of the LABD97 was also
performed. The amino acid sequences of these 14 peptides were identical to
amino acid sequences within the extracellular domain of BPAg2 (single
underlines).
a 97 kDa protein that reacted with LABD serum as shown in Fig 4
(lane 1). Coomassie blue stain of the column eluate (Fig 4, lane 2)
demonstrated the LABD97 protein as well as the 55 kDa mouse heavy
chain protein.
The N-terminal sequence of purified LABD97 is identical to a
sequence in the extracellular domain of BPAg2 N-terminal
sequencing was performed on the 97 kDa protein eluted from the
immunoaffinity column. This revealed a 16 amino acid sequence with
complete identity to a sequence of BPAg2 (NH2-A-G-A-D-L-D-K-
I-G-L-H-S-D-S-Q-E). The matching sequence (Fig 5, double underline)
in BPAg2 is located in the extracellular domain, 41 amino acids
Figure 6. Purified MoAb 97–1 and MoAb 97–2 do not convincingly
react with BPAg2 on immunoblot. Epidermal extract known to contain
large amounts of BPAg2 was separated on a 6% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (40 µg protein per lane) and transferred to
nitrocellulose. The lanes were incubated with BP serum known to react with
BPAg1 and BPAg2 (diluted 1:50, lane 1), MoAb 97–1 (purified antibody,
indirect immunofluorescence titer of 1:50,000, diluted 1:100, lane 2), MoAb
97–2 (purified antibody, indirect immunofluorescence of 1:50,000, diluted
1:100, lane 3), LABD patient sera (indirect immunofluorescence titers of ø
1:160, diluted 1:10, lanes 4–6), and normal human sera (diluted 1:10, lanes 7,
8). Lanes were subsequently incubated with appropriate secondary antibodies
(anti-human IgG, lane 1; anti-mouse IgG, lanes 2 and 3; anti-human IgA,
lanes 4–8). Under these conditions, the two purified monoclonal antibodies
demonstrated only weak reactivity with BPAg2 (lanes 2, 3) that was comparable
with the staining of background bands. As in earlier experiments, LABD sera
did not react with BPAg2 (lanes 4–6). HMW, high molecular weight standards.
downstream from the carboxyl end of the transmembrane domain
(Fig 5, dotted underline).
LABD97 has multiple amino acid sequences identical to those
in the extracellular domain of BPAg2 Purified LABD97 was
subjected to enzymatic digestion with endoproteinase Arg C and
separated by chromatography, which resulted in multiple peptide peaks.
Amino acid sequencing of 14 of these peptides revealed multiple
sequences identical to sequences within the extracellular domain of
BPAg2 (Fig 5, single underlines). Excluding hydroxylation of 11 prolines
(positions 622, 625, 628, 634, 687, 693, 696, 729, 882, 894, and
1263), which cannot be predicted from sequence deduced from cDNA,
the 14 LABD97 peptides were identical with predicted sequences of
extracellular BPAg2. Ten of the 14 peptides had a starting residue on
the carboxyl end of an arginine, as expected following digestion with
Arg C. In total, the 14 peptides yielded sequence totalling 205 amino
acids with a calculated molecular weight of µ20 kDa. These data
provide strong evidence that LABD97 is identical to a portion of the
extracellular domain of BPAg2. Moreover, examination of the amino
acid sequence of LABD97 reveals that the epitope recognized by
LABD sera is either within or adjacent to the collagenous portion of
BPAg2. In contrast, the predominant epitope identified with BP sera
is located in the noncollagenous region of BPAg2 (Fig 5, bold print).
Purified MoAb 97–1 and MoAb 97–2 do not convincingly react
with BPAg2 on immunoblot Initial evaluation of the reactivity
with MoAb 97–1 and MoAb 97–2 on immunoblot failed to identify
reactivity with BPAg2. Subsequent to the discovery that LABD97 was
identical to a portion of BPAg2, we performed additional immunoblot
analyses under varying conditions to evaluate reactivity of these
monoclonal antibodies with BPAg2. Even using high concentrations
of these monoclonals (1:100 dilution of antibody with a 1:50,000 titer),
we were able to demonstrate only weak reactivity with BPAg2. This
reactivity was significantly weaker than the reactivity of several lower
molecular weight bands that are background bands (Fig 6, lanes 2 and
3). We continued to be unable to detect any reactivity with BPAg2
using LABD sera, which had relatively low titers (ø1:160) (Fig 6,
lanes 4–6), as previously reported (Zone et al, 1990, 1996).
DISCUSSION
In 1990, we reported that IgA antibodies from the sera of patients
with the lamina lucida type of LABD reacted on immunoblot with a
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97 kDa antigen that could be extracted from human BMZ (Zone et al,
1990). We could not identify reactivity of LABD patient antibodies
with BPAg1 or BPAg2. We subsequently documented that IgA
antibodies from sera of patients with chronic bullous disease of
childhood reacted in a similar manner (Zone et al, 1996). In 1994,
Marinkovich described a monoclonal antibody that reacted with a 120
kDa antigen from keratinocyte culture medium as well as a 97 kDa
antigen from human skin extracts (Marinkovich et al, 1996). The
patient sera used in our original description (Zone et al, 1990) bound
the 120 kDa antigen. Neither this monoclonal antibody nor LABD
patient sera reacted on immunoblot with BPAg2. This resulted in the
conclusion that the 97 kDa antigen was a proteolytic fragment of a
larger 120 kDa antigen secreted in keratinocyte culture medium and
was distinct from BPAg2.
Pas et al (1997) have recently described subsets of bullous pemphigoid
and LABD patients with circulating antibodies that bind 120 kDa
antigens. These antigens appeared to be identical to each other in
biochemical and immunodepletion studies. Furthermore, this protein
was absent in the medium from keratinocytes cultured from patients
deficient in BPAg2. Some patient sera showed cross-reactivity with
both the 120 kDa protein and BPAg2, whereas others did not. They
suggested that there are unique epitopes on the 120 kDa protein,
because there were both BP and LABD sera that do not react with
BPAg2 but did react with this 120 kDa protein.
Our studies extend these observations on the similarity between the
protein that binds LABD sera and BPAg2. We developed a monoclonal
antibody that reacted with the LABD97 and used it to purify LABD97
from epidermal extract. It is important to note that the purified
protein reacted strongly with LABD patient sera, confirming that the
immunoaffinity column successfully isolated the antigenic protein. The
amino acid sequences obtained from the purified 97 kDa protein
demonstrate that this protein is identical to a portion of the extracellular
domain of BPAg2. This is based on the identity of the N-terminal
sequence of LABD97, as well as the identity of multiple internal
regions with the predicted amino acid sequence of BPAg2. The N
terminus of LABD97 is located near the midpoint of BP180 and just
downstream from the transmembrane and MCW-1 portions (Fig 1).
The amino acid sequences of LABD97 did not include any of the
distal 288 amino acids of BPAg2. It is possible that this carboxy-
terminal portion of the molecule represents the portion of the 120
kDa protein that has been proteolytically cleaved, producing the 97
kDa molecule.
Because the BP/herpes gestationis epitope is located in the MCW-
1 domain (Liu et al, 1993) that is not included in LABD97, it is clear
that the epitope for the IgA antibodies in LABD is distinct from the
epitope in BP.
It is not clear why our previous studies, and those of others,
have not shown reactivity of LABD patients’ sera with BPAg2 on
immunoblot, although they do show reactivity with LABD97 and the
120 kDa protein (Zone et al, 1990, 1996; Dmochowski et al, 1993;
Marinkovich et al, 1996; Pas et al, 1997). We agree with Pas et al that
there are unique epitopes on the smaller protein that are not present
on the immunoblot of BPAg2. These may be conformational or post-
translational modifications unique to the smaller molecule. The 120
and the 97 kDa proteins may represent cleaved fragments of BPAg2,
which exist as such in vivo, or which occur after proteolytic digestion
in vitro, in which case their role in the BMZ would not be unique
from BPAg2. Alternatively, the smaller molecules could represent
alternative splicing products of the same BPAg2 gene and may serve a
structural role with BPAg2 in the BMZ.
Other antigens have been described to bind LABD sera. Wojnarowska
et al (1991) have described binding to a 285 kDa antigen that has not
been further characterized to date. Megahed et al described a 57 kDa
protein deduced from cDNA clones obtained from a λgt11 cDNA
expression library screened with serum from a patient with LABD.1
1Megahed M, Motoki K, McGrath J, LaForgia S, Uitto J. Cloning of the
human linear IgA disease gene (LADA) encoding a novel anchoring filament
protein, ladinin. J Invest Dermatol 106:832, 1996 (abstr.)
This protein was termed ladinin. Whereas it does appear to be a unique
protein, subsequent experiments have failed to confirm binding of
LABD antibodies to this protein and there is no evidence that it plays
an antigenic role in LABD (personal communication, J. Uitto).
In summary, LABD97 is identical to a portion of the extracellular
domain of BPAg2 that does not contain the predominant epitope in
the NC16a domain recognized by BP sera. The epitope for the IgA
immune response to this molecule differs from the IgG response.
The reason for this antibody class-related immunologic heterogeneity
remains to be determined.
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